Holen Sie sich die Stockscreener-App
14.32
0.00%
0.00
Handel nachbörslich:
14.32
Schlusskurs vom Vortag:
$14.32
Offen:
$14.37
24-Stunden-Volumen:
339.89K
Relative Volume:
0.72
Marktkapitalisierung:
$996.34M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-9.4834
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+11.18%
1M Leistung:
+14.74%
6M Leistung:
-2.39%
1J Leistung:
+39.57%
1-Tages-Spanne:
$14.17
$14.50
1-Wochen-Bereich:
$12.93
$15.00
52-Wochen-Spanne:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.32 | 964.00M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
What analysts say about Zymeworks Inc. stockGame-changing returns - jammulinksnews.com
Zymeworks Announces Pricing of $100.0 Million Public Offering - Finance Monthly
Zymeworks Inc. Stock Analysis and ForecastTremendous gains - jammulinksnews.com
Teacher Retirement System of Texas Cuts Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
What drives Zymeworks Inc. stock priceRapid wealth multiplication - Autocar Professional
Is Zymeworks Inc. a good long term investmentFree Buy/Sell Signal Notifications - PrintWeekIndia
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? - MSN
Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences - The Globe and Mail
Zymeworks to Report Second Quarter 2025 Financial Results and Ho - GuruFocus
Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
What makes Zymeworks Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
How Zymeworks Inc. stock performs during market volatilityFree Stock Market Practical Discussion Forums - Newser
Why Zymeworks Inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
Janney Montgomery Scott LLC Boosts Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks sees $3.62 million stock purchase by EcoR1 Capital - Investing.com Nigeria
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell Small Cap Comp Value Index - MarketScreener
Zymeworks Amends Warrant Agreement with EcoR1 Capital - TipRanks
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500 - Kalkine Media
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price - simplywall.st
SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) (ZYME) - Seeking Alpha
Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Transcript : Zymeworks Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - Revista ADVFN
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Nuveen Asset Management LLC - Defense World
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC - Defense World
BNP Paribas Financial Markets Takes $108,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN
Ameriprise Financial Inc. Sells 15,800 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):